Evaluation of Attention-deficit/Hyperactivity Disorder in Referred Patients to the PKU Clinic in Yazd, Iran ADHD in PKU
Iranian Journal of Child Neurology,
Vol. 17 No. 1 (2023),
3 January 2023
,
Page 111-118
https://doi.org/10.22037/ijcn.v17i1.35870
Abstract
Objective
Imbalance of phenylalanine (PA) to tyrosine level and decrease dopamine brain level in phenylketonuria (PKU) patients may be have a role in susceptibility of them to have attention-deficit/hyperactivity disorder (ADHD). This study was done to evaluate frequency of ADHD in referred patients to PKU Clinic in Yazd, Iran.
Materials & Methods
In this cross-sectional analytical study, all older than 3 years PKU patients who were referred to PKU Clinic of Shahid Sadoughi Hospital, Yazd, Iran in 2018 evaluated and ADHD symptoms in them was assessed via parent face-to-face interview. The patient had ADHD if had at least score of 20 in ADHD diagnostic rating scale via parent interview based on DSM-VI criteria.
Results
Fourteen boys and 21girls with mean age of 9.55±1.8 years were evaluated that 51.5% of diagnosed with PKU had ADHD. ADHD was more frequent in girls (77.8% vs. 41% in boys, P=0.03).
Mean age of diagnosis of PKU was significantly higher in patients with ADHD (52.54±15.65 months vs. 29.75±9.65 months, P = 0.03).
Mean of PA level in the last 6 months (15.59±5.95 vs. 8.72+5.18, P= 0.005) and mean of the last six PA level (14.76±4.71 vs. 8.96±3.86, P= 0.03) were significantly higher in ADHD group.
Conclusion
Prevalence of ADHD in phenylketonuria patients in present study was much more than other studies. Late diagnosis of PKU and long term high phenylalanine blood and brain level might be associated with its increased and neonatal screening, regular follow-up and continuous evaluation of PKU patients for ADHD symptoms should be performed.
- Phenylketonuria, ADHD, Phenylalanine, Children
How to Cite
References
References
Heidari, A., Arab, M. & Damari, B. A policy analysis of the national phenylketonuria screening program in Iran. BMC Health Serv Res 2021,21: 120.
Killian Ashe, Wendy Kelso, Sarah Farrand, Julie Panetta, Tim Fazio, Gerard De Jong, Mark Walterfang. Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments. Front Psychiatry 2019; 10: 561.
Hofman DL, Champ CL, Lawton CL, Henderson M, Dye L. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J Rare Dis 2018; 30; 13 (1):150.
Abdelrahim A Sadek, Mohammed H Hassan, Nesreen A Mohammed. Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years. Neuropsychiatr Dis Treat 2018; 14: 2551–2561.
Beckhauser MT, Beghini Mendes Vieira M, MoehleckeIser B, Rozone de Luca G, Rodrigues Masruha M, Lin J, Luiz Streck E. Attention deficit disorder with hyperactivity symptoms in early-treated phenylketonuria patients. Iran J Child Neurol 2020; 14(1): 93-10.3
Targum SD, Lang W. Neurobehavioral Problems Associated with Phenylketonuria. Psychiatry (Edgemont) 2009; 7(12):29–32.
Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. J Clin Child Adolesc Psychol 2018;47(2):199-212.
Gold MS, Blum K, Oscar-Berman M, Braverman ER. Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? Postgrad Med 2014;126(1):153-77.
Eduardo Vieira Neto, Heber de Souza Maia Filho, Claudia Braga Monteiro, Lilian de Mattos Carvalho, Thuane Silva da Cruz, Belisia Vasconcelos de Barros, Márcia Gonçalves Ribeiro.Behavioral and Emotional Problems in Early-Treated Brazilian Children and Adolescents with Phenylketonuria .Med Sci Monit 2018; 24: 7759–7769.
Shokri M, Karimi P, Zamanifar H, Kazemi F, Badfar GH, Azami M. Phenylketonuria screening in Iranian newborns: a systematic review and meta-analysis. BMC Pediatr 2020; 20: 352.
Fayyazi A, Salari E, Khajeh A, Gajarpour A. A comparison of risperidone and buspirone for treatment of behavior disorders in children with phenylketonuria. Iran J Child Neurol. 2014;8(4):33-38.
Urion DK. Attention deficit/hyperactivity disorders. Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, Behraman RE. Nelson Textbook of Pediatrics. California, Elsevier 2021; 21th edition, Pp: 2863-2874.
Jameson E, Remmington T. Dietary interventions for phenylketonuria. Cochrane Database Syst Rev. 2020 Jul 16;7(7):CD001304.
Karimzadeh P, Ahmadabadi F, Jafari N, Shariatmadari F, Nemati H, Ahadi A, et al. Study on MRI changes in phenylketonuria in patients referred to Mofid Hospital/Iran. Iran J Child Neurol 2014;8(2):53-6.
Akhavan Karbasi S, Golestan M, Fallah R, Sadr M. Prevalence of attention deficit hyperactivity disorder in 6 year olds of Yazd city. J Shahid Sadoughi Univ Med Sci 2008; 15(4):29-34.
Mohammadi MR, Ahmadi N, Kamali K, Khaleghi A, Ahmadi A. Epidemiology of psychiatric disorders in Iranian children and adolescents and its relationship with social capital, life style and parents’ personality disorders: Study Protocol. Iran J Psychiatry2017,12(1):66-72.
Wyrwich KW, Auguste P, Yu R., Zhang C, Dewees B, Winslow B, Yu S, Merilainen M, Prasad S. Evaluation of neuropsychiatric function in phenylketonuria: Psychometric properties of the ADHD Rating Scale-IV and Adult ADHD Self-Report Scale Inattention subscale in phenylketonuria. Value in Health 2015, 18(4), 404–412.
Saad K, Elserogy Y, Al-Atram AA, Mohamad IL, ElMelegy TT, Bjørklund G, et al. ADHD, autism and neuroradiological complications among phenylketonuric children in Upper Egypt. Acta Neurologica Belgica 2015;115(4):657-63.
Eduardo Vieira Neto, Heber de Souza Maia Filho, Claudia Braga Monteiro, Lilian de Mattos Carvalho, Thuane Silva da Cruz, Belisia Vasconcelos de Barros, Márcia Gonçalves Ribeiro. Behavioral and emotional problems in early-treated Brazilian children and adolescents with phenylketonuria .Med Sci Monit 2018; 24: 7759–7769
Bilder DA, Kobori JA, Cohen-Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab (2017) 121(1):1–8.
Arnett AB, Pennington BF, Willcutt EG, DeFries JC, Olson RK. Sex differences in ADHD symptom severity. J Child Psychol Psychiatry 2015; 56(6): 632–639.
Antshel KM, Waisbren SE. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. Journal of abnormal child psychology. 2003;31(6):565-74.
Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, et al. Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. Developmental Neuropsychology 2016;41(4):245-60.
Antshel KM, Waisbren SE. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol 2003;31(6):565–74.
Burton B, Grant M, Feigenbaum A, et al. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab2015;114(3): 415–424.
Feillet F, Macdonald A, Hartung Perron D, Burton B, Hartung D. Outcomes beyond phenylalanine: an international perspective. Mol Genet Metab 2010;99 Suppl 1: S79–S85.
- Abstract Viewed: 181 times